LivaNova PLC (LIVN)
| Market Cap | 3.02B |
| Revenue (ttm) | 1.15B |
| Net Income (ttm) | 17.55M |
| Shares Out | 53.96M |
| EPS (ttm) | 0.32 |
| PE Ratio | 174.81 |
| Forward PE | 18.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 546,398 |
| Open | 55.14 |
| Previous Close | 55.02 |
| Day's Range | 55.00 - 56.14 |
| 52-Week Range | 42.75 - 59.86 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | 64.00 (+14.41%) |
| Earnings Date | May 1, 2024 |
About LIVN
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable p... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price forecast is $64.0, which is an increase of 14.41% from the latest price.
News
LivaNova to Announce First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova will host a conference call to discuss its first-quarter 2024 results on Wed, May 1, 2024 at 1 p.m. London time (8 a.m. ET).
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its OSPREY clinical study has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 issued in a private offering.
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 in a private offering.
LivaNova to Present at the Barclays Global Healthcare Conference
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova announced Vladimir Makatsaria, CEO, will present in a fireside chat at the Barclays Conference in Miami, Florida at 10:45 am ET on March...
LivaNova Reports Fourth-Quarter and Full-Year 2023 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024.
LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced its Board of Directors named Vladimir A. Makatsaria as the Company's CEO and a member of the Board of Directors, effective March 1.
LivaNova to Wind Down Advanced Circulatory Support Business Unit
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced that it will commence immediately with an orderly wind down of the Advanced Circulatory Support Business Unit.
LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova will host a conference call to discuss its fourth-quarter and full-year 2023 results on Feb 21, 2024 at 8am ET.
LivaNova to Present at the Piper Sandler Healthcare Conference
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced Bill Kozy, Interim CEO and Board Chair will present in a fireside chat at Piper Sandler at 8:30 a.m. ET on November ...
LivaNova Reports Third-Quarter 2023 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC reported results for the quarter ended Sept. 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guid...
LivaNova to Present at the Stifel and Wolfe Healthcare Conferences
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced Bill Kozy, Interim CEO and Board Chair, will present at Stifel and Wolfe Healthcare Conferences on Nov. 14 & 15, respectiv...
LivaNova Board Appoints J. Christopher Barry as New Director
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced its Board of Directors today appointed J. Christopher Barry to the Board and Andrea Saia will retire from the Board on Dec...
LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced that Marco Dolci intends to retire as President of the Cardiopulmonary Business Unit by December 31, 2023.
LivaNova to Announce Third-Quarter 2023 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its third-quarter 2023 results on November 1, 2023 at 12 p.m. London time (8 a.m. Eastern Tim...
LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced it received U.S. FDA 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor.
LivaNova to Present at the Baird Global Healthcare Conference
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced Bill Kozy, Interim CEO and Board Chair, will present at the Baird Global Healthcare Conference in New York on September 12...
LivaNova Reports Second-Quarter 2023 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC, a market-leading medical technology company, reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidanc...
LivaNova to Announce Second-Quarter 2023 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m. London time (8 a.m. ET)...
LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study.
Primecap Management Pumps Up LivaNova Position
Media-shy investment firm PRIMECAP Management (Trades, Portfolio) revealed earlier this week it upped its stake in LivaNova PLC ( LIVN , Financial), which had an impact of 0.04% on the equity portfoli...
LivaNova Reports First-Quarter 2023 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance.
LivaNova Board of Directors Announce Leadership Changes
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald has resigned as Chief Executive Officer. Effectiv...
LivaNova to Announce First-Quarter 2023 Results
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, Ma...
LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance f...